Section of Old Age Psychiatry, Institute of Psychiatry, London
Maudsley Hospital, London, UK
Department of Neuroscience, Institute of Psychiatry, London
Department of Pathology, Institute of Psychiatry, London
Department of Neuroscience, Institute of Psychiatry, London, UK
Correspondence: Professor S. Lovestone, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
Declaration of interest This work was completed in the course of research funded by the Medical Research Council and the Wellcome Trust.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Aims To describe the clinical features and molecular pathology changes in a single case of a patient with frontal lobe dementia.
Method A case report was compiled from neuropathological reports and genomic and gene expression analyses.
Results A case with a splice-site mutation resulting in a typical frontotemporal clinical and neuropathological phenotype was found. Gene expression analysis suggests differential expression of isoforms of tau in regions in the brain.
Conclusions Frontotemporal dementia can result from gene mutations that alter splicing and expression of tau.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
CASE HISTORY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
At this assessment she reported depressive symptoms, including suicidal ideation, of several years' duration. Her alcohol intake had increased markedly during the previous year. However, she seemed to become intoxicated on relatively small amounts of alcohol. Her husband also described her worsening memory, poor attention and distractibility. In addition she had become increasingly obsessional and inflexible. During the interview she was disinhibited and over-familiar. Her family described her as always having been eccentric but otherwise outgoing, generous and friendly. She loved singing in her local choir.
The patient's family tree is illustrated in Fig. 1. Her mother developed dementia in her fifties and died after a slowly progressive illness at the age of 72 years. Her father died at the age of 85 years without developing dementia. An older sibling developed a dementia diagnosed as Pick's disease at the age of 43 years and a cousin developed early-onset Alzheimer's disease.
|
At first presentation a physical and neurological examination was normal, as were routine blood screening tests for dementia and a computed tomography (CT) brain scan. Single photon emission tomography (SPET) revealed decreased uptake in both hemispheres of the brain, particularly in the frontal and temporal regions. There was a focal deficit in the left frontal region (Fig. 2). The results of neuropsychological examinations soon after presentation and on two subsequent occasions are shown in Table 1. A clinical diagnosis of Pick's disease or FTD was made.
|
|
During the patient's illness she regularly attended an old age psychiatry day hospital as well as a local authority specialist day centre for people with dementia. An intensive home care package was instituted when she could no longer be left unsupervised. Treatment at the day hospital included symptomatic use of a number of antidepressant drugs and an empirical trial of donepezil. None of these drug treatments gave any lasting benefit. During the earlier phase of her illness she received individual supportive psychotherapy and creative arts therapy, including painting, that continued until her final admission (Fig. 3).
|
Over the following 3 years she became gradually more disinhibited, was accused several times of shoplifting, became apathetic and neglected her personal care, and continued to complain of depression and suicidal thoughts. At the age of 55 she became incontinent of urine and lost the ability to help with housework or cooking. Later that year she started wandering in the neighbourhood when left unsupervised, even though she was still able to sing in her choir with some skill. By the age of 57 she had become doubly incontinent, was severely ataxic, akinetic and virtually mute. She was admitted to a nursing home but died from bronchopneumonia shortly after her 58th birthday.
![]() |
NEUROPATHOLOGY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The neuronal inclusions were of various configurations ranging from typical neurofibrillary tangles through more circumscribed Pick-like bodies to diffuse staining of cytoplasm. The glial inclusions affected both oligodendrocytes in the form of coiled bodies and astrocytes. The other prominent histological abnormality was the presence of large numbers of swollen, achromatic neurons: these were most numerous in the frontal lobe, present in smaller numbers in the temporal lobe, and occasionally present in the parietal cortex (Fig. 4a).
The hippocampus showed neuronal loss mainly from the CA1 area, many Hirano bodies, occasional granulovacuoles and neurofibrillary tangles. However, the dentate fascia was well preserved, showing only an occasional tau-positive tangle, but no typical Pick inclusions. In the basal ganglia including the caudate and the lentiform nuclei as well as in the thalamus there was mild to moderate neuronal loss with accompanying astrocytosis together with neuronal and glial inclusions. Of the pigmented nuclei of the brain-stem, the substantia nigra showed severe pathological changes including neuronal loss, some astrocytosis and tau-positive neuronal inclusions (Fig. 4b). The changes in the locus coeruleus were similar, but less severe. There were tau-positive glial inclusions also in the white matter.
In summary, the most significant histological lesions were tau-positive neuronal and glial inclusions and swollen achromatic neurons accompanied by status spongiosus, astrocytosis and neuronal loss. There was no evidence of typical Pick inclusions. The brain also showed some Alzheimer-type abnormalities, including neurofibrillary tangles, neuritic plaques and the deposition of beta-amyloid. However, these changes did not fulfil the criteria of Alzheimer's disease.
Various tau mutations are associated with different neuropathological manifestations. However, more interestingly, the same mutation in this case exon 10+16 (C to T) may be associated with both clinical and neuropathological phenotypical variations. Neuropathologic investigation of 12 such cases showed that the distribution, type and severity of histological abnormalities varied not only from case to case, but also within the same brain (further details available from the author upon request).
Tau: an essential neuronal protein
The tau-positive inclusions seen in the brain of this patient are abnormal
but tau itself is an essential neuronal protein. Tau is predominantly
expressed in axons where it binds to and stabilises microtubules. These
structures are normal components of all cells, and in dividing cells
participate in chromosomal segregation during meiosis. In neurons, however,
microtubules have a highly specialised role in facilitating fast axonal
transport the process whereby organelles and other materials are
transported between the synapse and the cell body. Disruption of microtubules
is highly toxic and in Alzheimer's disease microtubules are lost from diseased
cells. This loss of microtubules accompanies the aggregation of tau into the
neurofibrillary tangles, described by Alois Alzheimer. The importance of tau
aggregation in Alzheimer's disease was, however, hotly disputed until
recently.
![]() |
MOLECULAR GENETICS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Clearly, mutations in the tau gene are a probable cause of familial dementia of early onset with marked frontal lobe features, as in this case. Mutations in the gene can be detected in life or from post-mortem material by sequencing. As most tau mutations are found in and around the microtubule binding domains we systematically sequenced exons 9, 10, 12 and 13 using primers previously described (Rizzu et al, 1999). We detected an exon 10+16 C to T substitution (Fig. 5), a previously noted mutation (Hutton et al, 1998).
|
![]() |
MOLECULAR BIOLOGY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We would predict therefore that 4R tau isoforms would predominate in the tau aggregates in the temporal and frontal lobes of patients with this mutation. Previously the expression of tau protein has been examined in FTD by Western blotting, and indeed it does seem that the proportion of 4R tau is higher in these cases (Buée & Delacourte, 1999). However, studies of protein expression have been, to date, relatively coarse being able to determine only the relative amounts of the different tau isoforms in fractions from large amounts of brain tissue.
We were interested not only in the amount of tau isoforms bound up in relatively insoluble tangles but also in the expression of tau isoforms in different regions of the brain. If the mutations do alter splicing, then the actual expression of tau should be altered. Furthermore, the possibility that the regional specificity of this form of dementia might be explained by regional specificity of tau isoform expression is one that has not been previously studied.
To investigate the altered tau gene expression associated with the +16 mutation, we used a novel form of real-time, quantitative reverse transcriptase polymerase chain reaction (RTPCR; Perkin-Elmer Corporation), enabling us to quantify the actual production of different forms of mRNA (PCR examines DNA and RTPCR first transcribes mRNA back to DNA). This technique enabled the determination of the ratio of mRNA coding for the tau 4R isoform to that coding for the tau 3R isoform, derived from the total mRNA extracted from the temporal lobe, frontal lobe and outer molecular layer of the cerebellum of this patient and from 10 non-dementia control subjects. Tissue samples were obtained as fresh-frozen specimens and had been pH optimised for mRNA extraction. The ratio of 4R/3R tau in the control brain samples was remarkably consistent but the study case showed a considerably higher ratio in the temporal lobe and a very low ratio in the frontal lobe (Fig. 6). Overall, the mean ratio of 4R/3R in the person with the mutation was higher than in the control subjects (1.33 v. 0.87), consistent with previous reports (Hutton et al, 1998).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Molecular genetics and biology of early-onset dementias
The finding of mutations in the tau gene has helped to clarify the
relationship between Alzheimer's disease and FTD and has served to emphasise
the importance of tangles in Alzheimer's disease. The finding that early-onset
familial Alzheimer's disease can be caused by mutations in the gene producing
amyloid precursor protein (APP), which is metabolised to create the amyloid
deposited in plaques in Alzheimer's disease, gave birth to the amyloid
cascade hypothesis. This theory, in which the production of amyloid is
an early event in Alzheimer's disease pathogenesis, was given substantial
support by the finding that the presenilin proteins (mutations of which also
give rise to familial Alzheimer's disease) are almost certainly enzymes that
metabolise APP. Further support comes from findings that head injury is a risk
factor for Alzheimer's disease and also increases amyloid deposition; that a
gene associated with late-onset Alzheimer's disease, APOE, may also
alter amyloid aggregation; and finally and most recently, that a region of the
genome associated with late-onset Alzheimer's disease is also associated with
circulating amyloid levels. Together these findings are so persuasive that the
relevance of neurofibrillary tangles composed of hyperphosphorylated tau in
Alzheimer's disease has been questioned, even though it is the presence of
tangles and not plaques that correlates best with cognitive decline.
The finding that mutations in tau were a cause of some cases of familial FTD restored the importance of tangle pathology in dementia. It suggests that while diverse mechanisms may result in amyloid deposition in Alzheimer's disease it is the subsequent tangle formation that is responsible for dementia. In other words, tangle formation is a sufficient and may even be a necessary factor in dementia, whereas amyloid formation is neither, although it is certainly an important primary cause. Understanding the aggregation of tau is therefore fundamental to understanding the pathogenesis of both Alzheimer's disease and FTD. Normally tau is bound to microtubules where it functions to stabilise this component of the cytoskeleton essential for axonal transport and hence normal neuronal functioning. In both disorders the aggregated tau is highly phosphorylated, and as tau in this form does not bind to microtubules it may be that increased phosphorylation is important in the pathogenesis of the tauopathies. In line with this, a transgenic mouse overexpressing an enzyme shown to phosphorylate tau has a neurodegenerative phenotype. This may have wider importance in psychiatry, as the enzyme concerned, glycogen synthase kinase 3, is inhibited by lithium at concentrations used to treat bipolar disorder. However, while phosphorylation may be relevant to Alzheimer's disease it is not the primary event in familial FTD, where the mutations either have no effect on phosphorylation or reduce it. Instead the mutations might reduce binding directly, and missense mutations in exons have been shown to have this effect in cells.
Expression of different tau isoforms is altered in FTD
In the case presented here, however, there is a third mechanism: neither
the phosphorylation of tau nor its functional ability is altered directly but
the production of different isoforms of tau is altered. We show here that this
alteration is different in different areas of the brain. Tau is expressed in
all neurons but there are clear regional differences in all dementias
apart from the obvious differences (such as frontal predominance in FTD), the
cerebellum is spared in FTD and Alzheimer's disease for example. The reason
for this regional specificity is not known, but our finding suggests regional
differential splicing may be one mechanism. It is not known why the change in
the expression ratio of 4R/3R tau results in disease but it has been shown
that there are both differences in function between the two isoform types and
that one will displace the other from microtubules.
Taking these observations together it can be concluded that increased phosphorylation, missense mutations and alteration in the 4R/3R ratio of tau all reduce microtubule binding and increase tau aggregation. This results in neuronal loss, atrophy and dementia. In FTD, as here, the cause is mutation; in Alzheimer's disease the cause must be amyloid production or aggregation. It follows that treatments under development to delay or prevent tau aggregation would be potentially useful in both Alzheimer's disease and FTD, whereas therapies directed towards amyloid would not be efficacious in FTD.
Clinical implications of the molecular biology and genetics of
FTD
The discovery of mutations in the tau gene has significantly advanced
understanding of dementia and hence the search for effective therapies.
However, before these advances can be realised there are other, immediate,
implications for families. The discovery of the mutations immediately opened
up the possibility of diagnostic and predictive testing. Diagnostic testing of
familial early-onset Alzheimer's disease now allows the definitive diagnosis
of dementia subtype in a high proportion of autosomal dominant dementias.
Predictive testing allows the determination of risk (given that penetration
appears to approach 100% the risk determined is near-absolute) in first-degree
relatives of affected persons. As there are many potential sites of mutations
in a number of genes it is essential first to determine the pathogenic
mutation in a particular family before pursuing predictive testing. Any
testing must be accompanied by full counselling using protocols first
developed for use in Huntington's disease.
Such predictive testing is extremely stressful and families need considerable support. There are as many reasons not to pursue testing as there are to do so. The outcome of testing for other autosomal dominant neurodegenerative conditions is variable. Overall it would appear that the outcome is beneficial with decreased stress at follow-up, although it should be noted that those seeking testing are self-selected and these findings are matched by others showing a small proportion being worse at follow-up, including some of those who learn they do not carry a mutation, with occasional reports of severe adverse outcomes. In this case members of the family have received some preliminary counselling and have decided not to pursue genetic testing, at least for the time being.
Is this case a sign of things to come for psychiatry? In some ways the answer is no: this is an uncommon autosomal dominant neurodegenerative disorder quite dissimilar to most neuropsychiatric, let alone general psychiatry cases. However, it is likely that the methods and skills necessary in the understanding and treatment of this person will be more widely applicable in the future. Specifically in relation to dementia, understanding of the molecular pathogenesis (based largely on families such as the one reported here) has advanced to such an extent that putative treatments are in the early stages of development. More generally, techniques including molecular genetics and post-genomic technologies such as RTPCR will find increasing relevance to psychiatric conditions. It will be important that our clinical skills maintain pace with these technical advances.
![]() |
Clinical Implications and Limitations |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LIMITATIONS
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Buée, L. & Delacourte, A. (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathology, 9, 681-693.[Medline]
D'Souza, I., Poorkaj, P., Hong, M., et al
(1999) Missense and silent tau gene mutations cause
frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting
multiple alternative RNA splicing regulatory elements. Proceedings
of the National Academy of Sciences USA,
96,
5598-5603.
Dumanchin, C., Camuzat, A., Campion, D., et al
(1998) Segregation of a missense mutation in the
microtubule-associated protein tau gene with familial frontotemporal dementia
and parkinsonism. Human Molecular Genetics,
7,
1825-1829.
Forstl, H., Besthorn, C., Hentschel, F., et al (1996) Frontal lobe degeneration and Alzheimer's disease: a controlled study on clinical findings, volumetric brain changes and quantitative electroencephalography data. Dementia, 7, 27-34.[Medline]
Goedert, M., Spillantini, M. G., Crowther, R. A., et al (1999) Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine, 5, 454-457.[CrossRef][Medline]
Hutton, M., Lendon, C. L., Rizzu, P., et al (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393, 702-705.[CrossRef][Medline]
Lindau, M., Almkvist, O., Kushi, J., et al (2000) First symptoms frontotemporal dementia versus Alzheimer's disease. Dementia, 11, 286-293.
Pickering-Brown, S., Baker, M., Yen, S. H., et al (2000) Pick's disease is associated with mutations in the tau gene. Annals of Neurology, 48, 859-867.[CrossRef][Medline]
Reed, L. A., Wszolek, Z. K. & Hutton, M. (2001) Phenotypic correlations in FTDP-17. Neurobiology of Aging, 22, 89-107.[CrossRef][Medline]
Rizzu, P., Van Swieten, J. C., Joosse, M., et al (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. American Journal of Human Genetics, 64, 414-421.[CrossRef][Medline]
Spillantini, M. G., Murrell, J. R., Goedert, M., et al
(1998) Mutation in the tau gene in familial multiple system
tauopathy with presenile dementia. Proceedings of the National
Academy of Sciences USA, 95,
7737-7741.
Varani, L., Hasegawa, M., Spillantini, M. G., et al
(1999) Structure of tau exon 10 splicing regulatory element
RNA and destabilization by mutations of frontotemporal dementia and
parkinsonism linked to chromosome 17. Proceedings of the National
Academy of Sciences USA, 96,
8229-8234.
Received for publication August 9, 2001. Revision received November 8, 2001. Accepted for publication November 14, 2001.
Related articles in BJP:
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |